Connect with us

Live Business Updates

Brutal crash at Novavax after FDA approval



The US Food and Drug Administration (FDA) has granted emergency use authorization for Novavax’s coronavirus vaccine NVX-CoV2373. The approval applies to people over the age of 18, the FDA announced on Wednesday. This is an important milestone for the biotech company. However, the news is massively sold on the stock exchange.

The data demonstrate that the known and potential benefits of the vaccine outweigh the known and potential risks in individuals 18 years and older, and that this vaccine may be effective in preventing Covid-19,” it said recommended The CDC has yet to follow suit.

The vaccine, of which two doses are required, has been available in Germany since the end of February. It’s based on a more traditional process than BioNTech/Pfizer’s and Moderna’s mRNA vaccines, so it’s seen as a possible alternative for people who are skeptical about it.


However, the joy about the FDA approval does not last long. In the weak overall market, the Novavax share lost over 20 percent in value in one day. Other vaccine titles are also losing disproportionately.

There was one days before politicalreport that promised approval on Wednesday. “Sell the News” is the motto on Thursday at Novavax. DER SHAREHOLDER continues to favor BioNTech’s paper in the Covid-19 vaccine sector.

(With material from dpa-AFX)

Notice of Conflicts of Interest:

The CEO and majority owner of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has taken direct and indirect positions on the following financial instruments mentioned in the publication or related derivatives that may benefit from any price development resulting from the publication: BioNTech, Pfizer and Novavax.




Spread the love
Click to comment

Leave a Reply

Your email address will not be published.